Corrigendum to ‘Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)’ The American Journal of Cardiology 119 (2017) 1576–1583
| Autor: | Thomas Gelzleichter, Laura Pascasio Harris, Kun Peng, Sofia Mosesova, Josh Lehrer, Kyra J. Cowan, Alexandr Vilimovskij, John D. Davis, Amos Baruch, Whittemore G. Tingley, Nageshwar Budha, Robert Kahn, John C. Davis |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.drug_class PCSK9 Low density lipoprotein cholesterol Monoclonal antibody Inflammatory biomarkers Coronary heart disease 03 medical and health sciences 0302 clinical medicine Internal medicine Cardiology medicine In patient 030212 general & internal medicine Cardiology and Cardiovascular Medicine business 030217 neurology & neurosurgery |
| Zdroj: | The American Journal of Cardiology. 122:527 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2018.01.010 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect